Have You Heard? — The GLP-1 Era | Teleport Strength
EDITION 006HAVE YOU HEARD? — THE GLP-1 ERA: OZEMPIC IS BREAKING YOUR PHYSIQUETELEPORT STRENGTH · 2026
HAVE YOU HEARD? — BODY COMPOSITION SERIES
// THE MUSCLE LOSS CRISIS NOBODY IS TALKING ABOUT
OZEMPIC ISBREAKING YOUR PHYSIQUE(IF YOU DON'T TRAIN LIKE THIS)
GLP-1 drugs are producing historic fat loss results. They're also quietly stripping muscle, bone density, and metabolic capacity from millions of people who have no idea it's happening. The research is clear. The solution is the barbell.
40%
Of weight lost on semaglutide that can come from lean mass
10.9%
Lean mass reduction on tirzepatide over 72 weeks (SURMOUNT-1)
2.6%
Hip bone mineral density lost on semaglutide in 52 weeks
12%
Of US adults who have used GLP-1 drugs for weight loss (2024)
01 // THE SCALE
The Weight Loss Revolution Nobody Planned For
Since the FDA approved semaglutide for chronic weight management in 2021 and tirzepatide in 2023, the use of GLP-1 receptor agonists has exploded. A 2024 survey found that approximately 12% of American adults have used incretin-based drugs for weight loss — with around 6% currently on them. These aren't fringe medications anymore. They are reshaping how an entire population thinks about body weight.
The results in clinical trials are genuinely remarkable. The STEP 1 trial showed semaglutide producing average weight loss of 15% over 68 weeks. The SURMOUNT-1 trial with tirzepatide showed losses of 15–21% of total body weight over 72 weeks — results that far exceed anything achievable through lifestyle modification alone, where sustained loss typically tops out at 5–10%.
Here's what the headlines don't say: a significant portion of that weight isn't fat.
~15%Average weight loss on semaglutide (STEP 1 trial, 68 weeks)
~21%Average weight loss on tirzepatide (SURMOUNT-1, 72 weeks)
25–40%Proportion of that weight loss coming from lean mass — in most trials
−6.92kgLean mass lost in STEP-1 (−13.2% of baseline lean mass)
02 // THE CRISIS
The Muscle Loss Nobody Is Talking About
GLP-1 drugs work by suppressing appetite through hormonal signaling — reducing hunger, slowing gastric emptying, and creating a sustained caloric deficit that most people cannot achieve through willpower alone. That mechanism produces real fat loss. The problem is that the body in a large caloric deficit does not selectively burn fat. It also mobilizes protein from muscle tissue — and without the right countermeasures, the results on body composition can be quietly devastating.
// STEP-1 TRIAL — SEMAGLUTIDE DXA DATA
−6.92 kg lean mass · −13.2% of baseline · 45.2% of total weight lost from lean tissue
In the landmark STEP-1 trial, participants on semaglutide lost an average of 15.3 kg total — but 6.92 kg of that came from lean mass, not fat. That's nearly 45% of all weight lost coming from muscle, bone, organ, and connective tissue. The fat reduction was real and significant. The collateral damage was also real and significant.
−5.67 kg lean mass · −10.9% baseline · Fat loss: −33.9% vs 8.2% placebo
The SURMOUNT-1 DXA substudy (Look et al., Diabetes Obesity & Metabolism, 2025) provided the most detailed body composition data on tirzepatide to date. Tirzepatide reduced total fat mass by 33.9% — genuinely impressive. But lean body mass also decreased by 10.9%, compared to 2.6% with placebo. In absolute terms: nearly 6 kg of muscle-containing tissue gone in 72 weeks.
Semaglutide reduced hip BMD by 2.6% and lumbar spine BMD by 2.1% in 52 weeks
A 2024 phase 2 RCT (Hansen et al., eClinicalMedicine) found that one year on semaglutide reduced hip bone mineral density by 2.6% and lumbar spine density by 2.1% compared to placebo — with increased bone resorption and no compensatory bone formation. This occurred in parallel with weight loss but was not fully explained by mechanical unloading alone, suggesting a direct hormonal mechanism. For patients losing this much lean mass and bone density simultaneously, the long-term musculoskeletal risk is serious.
Source: Hansen et al., eClinicalMedicine 2024 · Jeremy Burnham MD, 2025 clinical review
// WHO IS MOST AT RISK
Women and older adults face disproportionately higher muscle loss on semaglutide
Research presented at ENDO 2025 (Haines, Massachusetts General Hospital / Harvard Medical School) found that older adults and women appear to be at significantly higher risk for lean mass loss on semaglutide. This matters because muscle is the primary regulator of blood sugar after meals and is critical for bone health and frailty prevention. Losing too much muscle while on a GLP-1 drug may actually reduce the metabolic benefits the drug was supposed to provide — including insulin resistance improvements.
Source: Haines M., ENDO 2025 Annual Meeting, Endocrine Society · July 2025
03 // THE MECHANISM
Why GLP-1 Drugs Take Your Muscle
GLP-1 drugs don't directly destroy muscle. The mechanism is more indirect — and more preventable than most people realize.
01
📉
Caloric Deficit Catabolism
Any large caloric deficit — drug-induced or otherwise — shifts the body into a catabolic state where protein from muscle is mobilized for fuel and gluconeogenesis. The larger and faster the deficit, the more lean tissue is sacrificed alongside fat.
// CATABOLISM
02
🍽️
Appetite Suppression = Protein Deficit
GLP-1 drugs dramatically reduce appetite — including appetite for protein-rich foods. Most users on these medications fall well below the protein intake required to preserve muscle. Without adequate leucine signaling, mTOR goes quiet and muscle protein synthesis drops.
// PROTEIN
03
🛌
No Mechanical Stimulus
Muscle is maintained through use — specifically through the mechanical tension of resistance training activating mTOR and triggering muscle protein synthesis. Most GLP-1 patients are not resistance training. Without the signal to keep muscle, the body has no reason to pay the metabolic cost of maintaining it during a deficit.
// mTOR
04
⚡
Metabolic Rate Collapse
Muscle is metabolically expensive tissue. When it's lost, resting metabolic rate drops. This means the long-term weight maintenance problem becomes significantly harder. The drug creates weight loss — but without muscle preservation, the rebound risk after stopping is dramatically elevated.
// RMR
04 // THE SOLUTION
Strength Training as Muscle Preservation Protocol
The 2025 case series from Texas Tech University (PMC12536186) is the most important piece of research for trainers working with GLP-1 patients. Three patients on semaglutide or tirzepatide who engaged in resistance training 3–5 days per week and consumed 1.6–2.3g of protein per kg of fat-free mass daily achieved dramatically different outcomes than typical clinical trial populations.
// TEXAS TECH CASE SERIES — WHAT HAPPENS WHEN YOU TRAIN
2 of 3 GLP-1 patients preserved or INCREASED lean mass while losing 13–33% of body weight
Results from three patients combining GLP-1 therapy with structured resistance training and high protein intake:
Case 1: −33% body weight · −53.4% fat mass · −6.9% lean mass (8.7% of weight loss from lean) Case 2: −26.8% body weight · −61.6% fat mass · +2.5% lean mass Case 3: −13.2% body weight · −46.9% fat mass · +5.8% lean mass
Two patients increased lean mass while losing substantial body fat on a GLP-1 drug. This is the outcome most people on these medications never achieve because nobody tells them how.
Source: PMC12536186 · Texas Tech University IRB2025-79 · Published 2025
// THE BELIEVE TRIAL — BIMAGRUMAB + SEMAGLUTIDE (ADA 2025)
Combination approach: 92.8% of weight loss from fat vs 71.8% for semaglutide alone
The BELIEVE Phase 2b trial (presented at the American Diabetes Association's 85th Scientific Sessions, June 2025) combined the experimental muscle-preserving antibody bimagrumab with semaglutide in 507 participants. The combination produced 92.8% of total weight loss from fat — compared to 71.8% for semaglutide alone. Critically, in patients taking bimagrumab alone, 100% of weight loss came from fat and lean mass increased by 2.5%. The researchers called this "the new direction of obesity treatment." While bimagrumab isn't widely available yet, the trial proves the concept: fat loss and muscle preservation are simultaneously achievable with the right protocol.
Source: BELIEVE Phase 2b Trial · ADA 85th Scientific Sessions, Chicago June 23, 2025 · Heymsfield et al.
The pharmaceutical industry's answer to muscle loss on GLP-1 drugs is another drug. The trainer's answer is the barbell, protein, and a plan.
01
🏋️
Resistance Training 3–5x/Week
Progressive overload activates mTOR — the anabolic signaling pathway that drives muscle protein synthesis. This is the direct mechanical signal that tells the body to preserve muscle even in a caloric deficit. Without it, the body has no reason to maintain tissue it isn't using.
// PRIMARY TOOL
02
🥩
1.6–2.3g Protein/kg FFM
Research from the Texas Tech case series used 1.6–2.3g/kg of fat-free mass as the protein target — above standard recommendations specifically because GLP-1 patients have suppressed appetite making adequate protein intake difficult. Leucine-rich protein sources (meat, eggs, dairy) directly activate mTOR.
// PROTEIN
03
📊
DXA Baseline + Tracking
Anyone on a GLP-1 drug should know their body composition before, during, and after treatment. Scale weight tells you nothing about whether you're losing fat or muscle. DXA scanning tracks lean mass, fat mass, and bone density — the three variables that determine whether the drug is doing what you actually want.
// MONITORING
04
🦴
Bone Density Protocol
Given semaglutide's documented effect on hip and lumbar spine bone mineral density, resistance training — which is one of the most powerful drivers of bone formation — is not optional for long-term GLP-1 users. Vitamin D3, K2, calcium, and collagen peptides support the bone remodeling that weight-bearing exercise stimulates.
// BONE HEALTH
05 // THE DATA
GLP-1 + Training vs. GLP-1 Alone
The difference between a GLP-1 patient who trains and one who doesn't isn't marginal — it's the difference between transforming your physique and dismantling it.
Outcome Measure
GLP-1 Alone (typical)
GLP-1 + Resistance Training + Protein
% Weight loss from fat
55–75%
Up to 100% (bimagrumab combo) / 90%+ with training
Lean mass change
−10.9% to −13.2%
Preserved or increased (+2.5% to +5.8%)
Bone mineral density
−2.1% to −2.6% in 52 weeks
Resistance training is primary bone formation stimulus
Resting metabolic rate
Decreases with lean mass loss
Maintained / increased with muscle preservation
Insulin sensitivity
Improved — but limited by muscle loss
Maximized — muscle is primary glucose sink
Post-drug rebound risk
High — reduced RMR + no muscle base
Lower — preserved metabolic capacity
Long-term frailty risk
Elevated — especially in women, older adults
Reduced — strength base protects against sarcopenia
06 // THE TELEPORT STRENGTH ANGLE
Strength Training Is Now a Medical Protocol
The GLP-1 era has changed the role of a strength coach. The conversation is no longer primarily about aesthetics or performance. Strength training is now a medically supported intervention for protecting the physique of the 12% of Americans actively taking weight-loss medications.
These individuals have a drug doing the hard work of creating a caloric deficit. What they don't have — unless someone coaches them — is a plan to preserve the tissue that determines their long-term health, metabolic rate, insulin sensitivity, bone density, and physical capability. That's the gap that a strength coach fills in 2025 and beyond.
Every GLP-1 patient needs a muscle preservation protocol. Research is unambiguous: resistance training 3–5x per week paired with adequate protein is the only lifestyle intervention proven to protect lean mass during pharmacologically-driven weight loss.
Protein isn't optional — it's the co-drug. GLP-1 patients on protein targets of 1.6–2.3g/kg fat-free mass preserved and even built lean mass while losing 13–33% of their body weight. Patients on default intake did not. Nutrition coaching is not a soft add-on — it's the mechanism of the result.
The scale is no longer the metric. Body weight means nothing in this population. Body composition — tracked by DXA — is the only honest scorecard. Coaches who can interpret and act on DXA data have a genuine clinical edge.
Bone density is now in scope. A 2.6% drop in hip bone density in a year is clinically significant, particularly for older women. Resistance training, Vitamin D3, K2, and calcium aren't wellness suggestions for GLP-1 patients — they're damage control.
The rebound problem is a training problem. Without muscle, the metabolic rate is lower post-drug than pre-drug. The rebound cycle continues. With muscle, the metabolic foundation is set for sustained long-term weight management — drug or no drug.
// COACH LIONEL'S TAKE
GLP-1 drugs are a genuine medical breakthrough for people struggling with obesity. The fat loss data is real, the metabolic benefits are real, and for many individuals these medications are genuinely life-changing. That's not the debate.
The debate is this: why is nobody telling these patients that they're losing their muscle at the same time? Why is nobody in the doctor's office handing them a resistance training protocol alongside the prescription? Why is the pharmaceutical industry developing a second drug to prevent the muscle loss caused by the first drug — when a barbell, adequate protein, and a coach would solve the same problem without a second injection?
The BELIEVE trial showed 92.8% of weight loss coming from fat when semaglutide is combined with a muscle-preserving intervention. Two out of three patients in the Texas Tech case series increased lean mass while losing over a quarter of their body weight on a GLP-1 drug.This is not a pharmaceutical achievement. This is what structured resistance training and protein-forward nutrition does.
If you or someone you know is on Ozempic, Wegovy, Mounjaro, or Zepbound — the drug handles the deficit. Teleport Strength handles the physique. That's the protocol. That's the mission.
